Skip to main content
. 2001 Jan;16(1):14–23. doi: 10.1111/j.1525-1497.2001.00249.x

FIGURE 5.

FIGURE 5

Average cost effectiveness as a function of prevalence of spinal cancer. The arrow indicates the prevalence of 0.66% used in the baseline analysis. HxCa indicates history of cancer; ESR, erythrocyte sedimentation rate.